Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran?
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: The objectives of the present trial were to compare the side effects and safety of two intravenous iron preparations (iron-dextran, iron-sucrose) in patients with end stage renal disease. METHODS: A total of 60 patients were randomized and assigned to one of two treatment groups (iron-dextran, n = 30; iron-sucrose, n = 30). A standard test dose of 25 mg of low molecular weight iron-dextran and iron-sucrose were administered over 15 minutes during the initial visit, monitoring very closely for adverse reactions. If this dose was well tolerated, 75 mg of iron diluted in 100 mL of normal saline was administered over 30 minutes. Adverse reactions were recorded. RESULTS: The mean age of the patients was 51.5+/-17.4 years (range, 21 to 80 years). Of the 30 patients who received low molecular weight iron-dextran, 11 developed side effects (pruritus, 1 patient; wheezing, 1 patient; chest pain, 1 patient; nausea, 4 patients; hypotension, 1 patient; swelling, 1 patient; headache, 2 patients). Of the 30 patients who received iron-sucrose, 13 developed side effects (pruritus, 1 patient; wheezing, 1 patient; diarrhea, 1 patient; nausea, 4 patients; hypotension, 2 patients; swelling, 1 patient; headache, 3 patients). Adverse events occurred with similar frequency in the two treatment groups in our study (p > 0.05). We did not observe any serious reactions in the two groups. CONCLUSION: We conclude that the incidence of side effects associated with iron-dextran was not different than that of iron-sucrose in our study. Large scale randomized studies are needed to compare the full side effect profile of intravenous iron preparations more precisely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
Auerbach, M., & Ballard, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.338 · Cited by 310
How we diagnose and treat iron deficiency anemia
Auerbach, M., & Adamson, J. W. (2016) · American Journal of Hematology · doi:10.1002/ajh.24201 · Cited by 308
Single-dose intravenous iron for iron deficiency: a new paradigm
Auerbach, M., & Deloughery, T. (2016) · Hematology · doi:10.1182/asheducation-2016.1.57 · Cited by 148
Intravenous iron therapy: how far have we come?
Cançado, R. D., & Muñoz, M. (2011) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20110123 · Cited by 94
Metadata
- Authors
- Sav, T., Tokgoz, B., Sipahioglu, M. H., Deveci, M., Sari, I., Oymak, O., & Utas, C.
- Venue
- Renal Failure
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 29
- Issue
- 4
- Pages
- 423-426
- ISSN
- 0886-022X (ISSN-L)
- 1525-6049
- OpenAlex
- W2062008424
- Cited by
- 71
- References
- 0
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran? https://app.cochat.ai/papers/10.1080/08860220701278208
- The paper
- Sav, T., Tokgoz, B., Sipahioglu, M. H., Deveci, M., Sari, I., Oymak, O., & Utas, C. (2007). Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran? Renal Failure. https://doi.org/10.1080/08860220701278208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.